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Conclusion: Community acquired meningitis by an organism of en-
teric flora in an immunocompromised patient should raise the sus-
picion of hyperinfection syndrome in endemic areas. Since eradi-
cation of parasite may be delayed, repeated stool examination and
prolonged treatment are required.
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Background: In patients with HIV/AIDS uncontrolled Epstein Barr
Virus (EBV) replication produces high viral loads that expand the
pool of latently infected cells vulnerable to development of B-
lineage tumors: non-Hodgkins lymphoma (NHL) and classic Hodgkin
lymphoma (HL). HAART accompanied by T-cell reconstitution dra-
matically reduced the incidence of EBV+ lymphomas, with the sur-
prising exception of HL. Though EBV+ HL, can be distinguished from
NHL by several criteria, a major difference is the grossly aneu-
ploid nature of the malignant RS cell, a post-germinal center B-cell
characterized by aberrant centrosomes and grossly abnormal chro-
mosomes. Although latent cycle products alone were believed to
promote viral tumorigenesis, accumulating evidence suggests lytic
cycle proteins also play a critical role. The lytic enzyme EBV thymi-
dine kinase (TK) is a modest dT kinase with a large N-terminus of
unknown function. It is present in the virion tegument and interacts
with multiple viral and cellular proteins forming a dominant node
in the viral interactome. How and why these diverse interactions
regulate virion production is entirely unknown. We recently found
that unique among herpesvirus proteins, EBVTK strictly localizes to
centrosomes. Significantly, upon lytic induction EBVTK is detected
in centrosomes containing structural and numerical abnormalities.
The centrosome is the master regulator of the microtubular cy-
toskeleton and controls the physical work of cell division. Minor
perturbations of centrosome content cause errors in chromosome
segregation, cytokinesis and cell cycle regulation, promoting ane-
uploidy and tumorigenesis.
Objective: To uncover the role(s) of EBVTK in control of lytic in-
fection and in development of centrosome abnormalities.
Methods: Biochemical characterization of native enzyme. Con-
struction and expression of wild type TK and a series of TK mu-
tants followed by microscopy to detect localization and pertur-
bation of centrosome/microtubule function in different cell types
(yeast-human).
Results: EBVTK is a phosphoprotein in eukaryotic cells; phosphory-
lation plays distinct roles in different enzyme functions.
Conclusions: EBVTK is a multifunctional protein that performs dis-
tinct roles during different stages of the virus life cycle. TK ex-
pression may predispose to centrosome abnormalities resulting in
aneuploidy as seen in EBV+ HL.
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Background: Zygomycosis is a life-threatening invasive fungal
infection most prevalent among immunocompromised patients.
Posaconazole (POS) is a novel antifungal triazole with activity
against zygomycetes. Granulocyte colony-stimulating factor (G-
CSF) is known to augment neutrophil activity, in vitro, and improve
the effects of antifungal drugs.
Objective: The aim of this study was to develop a neutropenic
murine model of disseminated zygomycosis and evaluate the effi-
cacy of POS alone or in combination with G-CSF.
Methods: Male Balb-c mice were infected via the lateral tail vein
with 5×104 conidia R. microsporus/mL. At 24 hour post-infection
the mice were divided in four groups of five. Each group was
treated with POS (40 mg/kg/day by gavage), or G-CSF (300 mi-
cro g/kg/day subcutaneously), or with the combination of POS+G-
CSF. In the control group, animals were treated with saline. Mice
were rendered neutropenic with cyclophosphamide (200 mg/kg,
intraperitoneally) administered on days –1 and +5. Mortality was
recorded for 10 days and survival was assessed with Kaplan-Meier
curves. The fungal burden of the brain, liver, kidneys and lungs
was evaluated with semi-quantitative cultures and statistical anal-
ysis was performed using arbitrary score units (n`mice).
Results: The mean survival times were 6.56±0.57 days for the con-
trols, 7.53±0.51 days for POS-treated mice (P=0.098 vs controls),
6.93±0.56 days for G-CSF-treated mice (P=NS) and 7.13±0.59
days for POS+G-CSF-treated mice (P=NS). Combination therapy
(P=0.022) as well as POS monotherapy (P=0.037) reduced signifi-
cantly the fungal burden in the kidneys. The reduction of fungal
burden in the rest of the organs was not statistically significant.
Conclusions: Posaconazole monotherapy and POS+G-CSF combina-
tion therapy had a modest efficacy against R. microsporus. Fur-
thermore, POS and combination therapy reduced significantly the
fungal burden in the kidneys, while a moderate reduction of fungal
burden was observed for the rest of the organs. Combining G-CSF
with POS did not substantially affect the antifungal efficacy of POS.
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Background: Hematogenous Candida meningoencephalitis (HCME)
is a common complication of candidemia in immunocompromised
pediatric patients, particularly neonates, resulting in abscesses,
seizures, ventricular hemorrhage, mental retardation, and death.
CSF cultures are often negative and early diagnosis of HCME is dif-
ficult.
Objectives: To characterize the potential diagnostic utility of CSF
(1→3)-β-D-glucan as a biomarker for the detection and therapeutic
monitoring of HCME.
Methods: The kinetics of expression of (1→3)-β-D-glucan in blood
and CSF was studied in a well-established non-neutropenic rab-
bit model of HCME caused by Candida albicans. Levels of (1→3)-
β-D-glucan were measured by factor G Limulus assay (Cape Cod
Associates). Micafungin (MICA) (0.5 to 32 mg/kg/d IV) and deoxy-
cholate amphotericin B (DAmB) (1 mg/kg/d IV) were administered
to study the effects on expression of (1→3)-β-D-glucan for thera-
peutic monitoring.
Results: Among untreated controls (UC) (n=25), C. albicans es-
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tablished multiples abscesses in cerebrum, cerebellum, choroid,
vitreous humor, spinal cord, and meninges, where two (8.1%) of
25 CSF cultures were positive and 25 (100%) of simultaneous CSF
samples for (1→3)-β-D-glucan were positive with a range of 755
to 7750 pg/mL (p<0.001). Levels of (1,3)-β-D-glucan in CSF were
significantly greater than those of simultaneously obtained serum
samples in treated animals (n=94) and UC (p<0.05), suggesting
CNS compartmentalization of this polymeric biomarker. Clearance
of C. albicans from blood cultures was not predictive of eradica-
tion of organisms from CNS; whereas, reduction of CSF (1→3)-β-D-
glucan levels was predictive of therapeutic response. A significant
decrease of (1→3)-β-D-glucan concentration of CSF started at 0.5
mg/kg/day in comparison to that of UC (p<0.001). Fungemia per-
sisted in all untreated controls. Positive blood cultures converted
to negative with MICA and DAmB within one day after treatment,
while CNS tissues remained positive for C. albicans. By compar-
ison, CSF (1→3)-β-D-glucan levels correlated directly in a dose-
dependent pattern with therapeutic response and residual fungal
burden of C. albicans in cerebral tissue (r=0.842).
Conclusions: (1→3)-β-D-Glucan in CSF is a surrogate marker for
detection and therapeutic response of hematogenous candida
meningoencephalitis.
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Background: Zygomycetes are emerging fungal pathogens that
cause life-threatening pneumonia in cancer patients, especially
during prolonged neutropenia and corticosteroid therapy. Little
is known about the relation between different species of Zy-
gomycetes and their pathogenesis in pulmonary zygomycosis.
Objectives: To study the relative virulence of Rhizopus oryzae
(RO), Rhizopus microsporus (RM), Mucor circinelloides (MC), Mu-
cor indicus and Cunninghamella bertholletiae (CB) in experimental
pulmonary zygomycosis and the possible correlation with germina-
tion rate, metabolic activity, and circulating zygomycete-specific
DNA by qPCR.
Methods: Interspecies virulence was studied in experimental pri-
mary pulmonary zygomycosis in persistently neutropenic rabbits
by a panel of validated outcome variables. Sporangiospore germi-
nation kinetics were measured over 4 h. Hyphal metabolic activ-
ity was determined by XTT assays. Plasma levels of zygomycete-
specific DNA, as a surrogate biomarker for angioinvasion, were
measured by qPCR of two regions within the 28S rRNA gene.
Results: There were significant inoculum-dependent differences
in residual pulmonary fungal burden (CFU/g) among CB-, RM-,
and RO-infected rabbits (102-104 CFU/g, p<0.05), and significant
differences in organism-mediated pulmonary injury as measured
by lung weights in RM-, and RO-infected rabbits (p<0.05). CB
caused the highest lung weights, most extensive pulmonary
infarcts, and lowest survival of 0% (0/18), in comparison to 16%
(3/18, p<0.01) of RM-, 81% (21/26) of RO- and 83% (15/18) of M-
infections (p<0.001). Differences in virulence correlated with dif-
ferent germination kinetics at 4 h: CB (67-85%) > RM (14-56%) > RO
(4-30%) > MC and MI (0%). These data correlated with greater in
vitro metabolic activity by XTT assay of CB at 6 h (OD450=1.22)
in comparison to that of RM, RO, MC and MI (0.37-0.84). Mean
peak plasma zygomycete-specific DNA concentration (log GE/ml)
followed a similar pattern: CB > RM > RO > MC.
Conclusions: Medically important species of Zygomycetes differ
significantly in the outcome of pulmonary zygomycosis. Cunning-
hamella bertholletiae and Rhizopus microsporus were significantly
more virulent than Rhizopus oryzae and Mucor species. Viru-
lence parameters of zygomycosis in vivo correlate with species-
dependent differences in germination kinetics, hyphal metabolic
activity, and circulating levels of zygomycete-specific DNA.
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Background: Influenza vaccination is less immunogenic in trans-
plant recipients than healthy people. Influenza A (H1N1) and B
circulating viruses during the 2007-2008 epidemic were different
from those contained in this season' s vaccine.
Objective: To describe clinical and immunological characteristics
of 15 transplant recipients who developed influenza despite in-
fluenza vaccination (group A), and compare them to 6 transplant
recipients who developed influenza in the absence of influenza
vaccination (group B), 13 transplant recipients who did not develop
influenza (group C), and 8 healthy people who developed influenza
(group D.)
Methods: Case ascertainment through microbiology and electronic
medical records.
Results: Types of transplant: liver 3, heart 7, kidney 3, lung 8,
HSCT 8, kidney + pancreas 3, liver + kidney 1, liver + pancreas 1.
20 had influenza A, and 10 had influenza B (1 transplant recipi-
ent has both simultaneously.) Influenza occurred 1757 days (mean
[range 0-3850]) after transplant in group A, compared to 801 days
(range 20-3082) in group B. Influenza occurred 116 days (mean
[range 83-151] after vaccination in group A. There were no sta-
tistically significant differences in the incidence of fever, cough,
rhinorrhea, sore throat, malaise, shortness of breath, exposure to
contacts with similar symptoms, or presence of infiltrates on CXR
among groups A, B and D. Groups A and B were treated with os-
eltamivir significantly more frequently than Group D, [p=0.002].
Patients in group A were hospitalized more frequently than group
D [p=0.0002]. There were no statistically significant differences
in the incidence of pneumonia, ICU admission, mechanical ventila-
tion, or death among groups A, B and D. There were no statistically
significant differences between groups A, B and C in the incidence
of IgG < 600 mg/dL, immune function assay < 200 ng/mL, rejec-
tion (in SOT recipients) or GVHD (in HSCT recipients) in the pre-
ceding 30 days. Patients in group A were significantly more likely
to have concomitant infections than group D [p=0.049], but not
group B.
Conclusions: Influenza vaccination did not alter clinical presenta-
tion of influenza in transplant recipients, or impact the incidence
of complications. Transplant recipients who developed influenza
despite influenza vaccination were not more immunosuppressed
than those who were vaccinated and did not develop influenza,
and were more likely to have concomitant infections than healthy
people.
